A5061254771- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Cancer Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Wnt/β-catenin signaling in development and cancer
- Cancer, Hypoxia, and Metabolism
- Peptidase Inhibition and Analysis
- Brain Metastases and Treatment
- Epigenetics and DNA Methylation
- Polyomavirus and related diseases
- Colorectal Cancer Treatments and Studies
- Renal and related cancers
- Pancreatic and Hepatic Oncology Research
- Mechanisms of cancer metastasis
- Antenna Design and Analysis
- Extracellular vesicles in disease
- Medical Imaging Techniques and Applications
- Plant Virus Research Studies
- Advanced Breast Cancer Therapies
- Prenatal Screening and Diagnostics
- Prostate Cancer Treatment and Research
- Hematopoietic Stem Cell Transplantation
- Metastasis and carcinoma case studies
- Polyamine Metabolism and Applications
- Cellular Mechanics and Interactions
Université de Montpellier
2015-2025
Maladies Infectieuses et Vecteurs: Écologie, Génétique, Évolution et Contrôle
2021-2025
Institut de Recherche pour le Développement
2021-2025
Centre National de la Recherche Scientifique
2021-2025
Centre Hospitalier Universitaire de Montpellier
2015-2023
Ecologie & Evolution
2023
Agropolis International
2023
Biologie Labor
2019-2020
Institut Universitaire de Recherche Clinique
2018
Neuropsychiatrie : Recherche Epidemiologique et Clinique
2015-2018
Immune checkpoint regulators such as PD‐L1 have become exciting new therapeutic targets leading to long lasting remissions in patients with advanced malignancies. However, view of the remarkable costs and toxicity profiles these therapies, predictive biomarkers able discriminate responders from non‐responders are urgently needed. In present paper, we provide evidence that is frequently expressed on metastatic cells circulating blood hormone receptor‐positive, HER2‐negative breast cancer...
Circulating tumor cells (CTC) in blood are promising new biomarkers potentially useful for prognostic prediction and monitoring of therapies patients with solid tumors including colon cancer. Moreover, CTC research opens a avenue understanding the biology metastasis However, an in-depth investigation CTCs is hampered by very low number these cells, especially colorectal Thus, establishment cell cultures permanent lines from has become most challenging task over past year. Here, we describe,...
The choice between chemotherapy and endocrine therapy as first-line treatment for hormone receptor-positive, ERBB2 (also known HER2)-negative metastatic breast cancer is usually based on the presence of clinical features associated with a poor prognosis. In this setting, high circulating tumor cell (CTC) count (≥5 CTCs/7.5 mL) strong adverse prognostic factor overall survival progression-free (PFS).To compare efficacy clinician-driven vs CTC-driven treatment.In CTC arm, patients received or...
Detection of circulating tumor cells (CTC) in breast cancer patients is currently performed many clinical trials, using different technologies, particular the EpCAM-dependent CellSearch® system. The purpose this study was to investigate incidence and prognostic relevance viable CTC a large cohort metastatic (MBC) patients.A total 254 MBC were enrolled prospective multicenter at first diagnosis disease or progression (before start new treatment regimen). After EpCAM-independent enrichment,...
Article15 July 2020Open Access Source DataTransparent process Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity Claudia Koch Department Tumor Biology, Center Experimental Medicine, University Medical Hamburg-Eppendorf, Hamburg, Germany Search for more papers by this author Andra Kuske Simon A Joosse orcid.org/0000-0002-4296-5615 Gökhan Yigit Institute Human Genetics, Göttingen, George Sflomos orcid.org/0000-0003-2972-0549 ISREC – Swiss Cancer...
In non-small cell lung cancer (NSCLC), analysis of programmed death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked biopsy spatiotemporal heterogeneity. However, prognostic significance PD-L1-positive [PD-L1(+)] CTCs remains controversial.We prospectively evaluated correlation with clinicopathological variables and value PD-L1(+) CTCs, detected FDA-cleared CellSearch® system, 54 patients advanced NSCLC.We 43.4% 9.4%...
Abstract Background Circulating tumour cells (CTCs), circulating DNA (ctDNA), and extracellular vesicles (EVs) are minimally invasive liquid biopsy biomarkers. This study investigated whether they predict prognosis, alone or in combination, heterogenous unbiased non-small cell lung cancer (NSCLC) patients. Methods Plasma samples of 54 advanced NSCLC patients from a prospective clinical trial. CtDNA mutations were identified using the UltraSEEK™ Lung Panel (MassARRAY® technology). PD-L1...
Circulating tumor cells (CTCs) are important clinical indicators for prognosis and treatment efficacy. However, CTC investigation is hampered by their low number, making the establishment of permanent lines very challenging. We derived characterized nine using blood samples from a patient with metastatic colorectal cancer collected before after chemotherapy targeted therapy, during progression. These cell displayed an intermediate epithelial/mesenchymal phenotype, stem-cell like...
Abstract BACKGROUND Unraveling the molecular mechanisms that regulate biology of metastasis-competent circulating tumor cells (CTCs) is urgently needed to understand metastasis formation and relapse. Our group previously established first cell line (CTC-MCC-41) derived from CTCs a patient with colon cancer. METHODS In this study, we analyzed transcriptome CTC-MCC-41 using Human Genome U133 Plus 2.0 microarrays aim unraveling basis their special features (stem properties ability initiate...
Abstract BACKGROUND This prospective multicenter study evaluated the prognostic value of circulating tumor cells (CTCs) in relapsing nonoperable or metastatic head and neck squamous cell carcinoma (rHNSCC) treated by chemotherapy cetuximab. METHODS In 65 patients suitable for analyses, peripheral blood was taken at day 0 (D0) D7, D21 treatment CTC detection CellSearch®, EPISPOT, flow cytometry (FCM). Progression-free survival (PFS) assessed with Kaplan–Meier method compared log-rank test (P...
Abstract Background Data regarding the prognostic value of programmed cell death ligand 1 (PD-L1) expression on circulating tumor cells (CTCs) are lacking. However, CTCs could represent an alternative approach to serial biopsies, allowing real-time monitoring cancer phenotype. Methods We evaluated, in a dedicated prospective clinical trial, clinicopathological correlations and PD-L1(+)-CTCs 72 patients with metastatic breast (MBC). Results Eighteen 56 available archival tissue presented at...
Abstract Background Pancreatic cancer, predominantly characterized by ductal adenocarcinoma (PDAC) accounts for 90% of cases and is the fourth leading cause cancer-related deaths globally. Its incidence notably increasing. This poor prognosis primarily due to late-stage diagnosis (approximately 70% 80% patients are diagnosed at an advanced stage), aggressive tumor biology, low sensitivity chemotherapy. Consequently, it crucial identify develop a simple, feasible reproducible blood-based...
Abstract Background Circulating tumor cells (CTCs) are pivotal in cancer progression, and vitro CTC models crucial for understanding their biological mechanisms. This study focused on the characterization of extracellular vesicles (EVs) from lines derived a patient with metastatic colorectal (mCRC) at different stages progression who progressed despite therapy (thus mirroring clonal evolution cancer). Methods results Morphological size analyses revealed variations among EVs lines. Compared...
Circulating tumor cells (CTCs) play an important role in metastasis formation. Aberrant signaling of oncogenic pathways (e.g., PI3K/AKT/mTOR pathway) drives progression. In this work, the susceptibility colon cancer CTC-derived cell line CTC-MCC-41 to AKT and mammalian target rapamycin (mTOR) inhibitors was evaluated. Additionally, functional expressed isoforms characterized line. The efficacy inhibitor MK2206, mTOR RAD001, combination examined a murine intracardiac xenotransplantation...
Circulating tumor cells (CTCs) are shed from the primary into bloodstream. While many studies on solid exist, data CTCs scarce. The mortality of cancer is mostly associated with metastasis and recent research identified as initiators metastasis. PI3K/AKT/mTOR signaling pathway an intracellular that regulates essential functions including protein biosynthesis, cell growth, cycle control, survival migration. Importantly, activating oncogenic mutations amplifications in this frequently observed...
Abstract Background The diagnosis of breast cancer (BC)-related leptomeningeal metastases (LM) relies on the detection tumor cells in cerebrospinal fluid (CSF) using conventional cytology (gold standard). However, sensitivity this technique is low. Our goal was to evaluate whether circulating cell (CTC) CSF CellSearch® system could be used for LM diagnosis. Methods This prospective, monocentric study included adult patients with suspected BC-related LM. clinical and specificity CTC were...
Metastatic melanoma is one of the most aggressive and drug-resistant cancers with very poor overall survival. Circulating cells (CMCs) were first described in 1991. However, there no general consensus on clinical utility CMC detection, largely due to conflicting results linked use heterogeneous patient populations different detection methods. Here, we developed a new EPithelial ImmunoSPOT (EPISPOT) assay detect viable CMCs based their secretion S100 protein (S100-EPISPOT). Then, compared...
Multiple technologies are available for detection of circulating tumor cells (CTCs), but standards to evaluate their technical performance still lacking. This limits the applicability CTC analysis in clinic routine. Therefore, context CANCER-ID consortium, we established a platform assess validity methods European multi-center setting using non-small cell lung cancer (NSCLC) as model.We characterized multiple NSCLC lines define cellular models distinct phenotype and molecular...
Background: Platelets are active players in hemostasis, coagulation and also tumorigenesis. The cross-talk between platelets circulating tumor cells (CTCs) may have various pro-cancer effects, including promoting growth, epithelial-mesenchymal transition (EMT), metastatic cell survival, adhesion, arrest pre-metastatic niche metastasis formation . Interaction with CTCs might alter the platelet transcriptome. However, as rare events, is poorly understood. Here, we used our established colon...
Metastasis is a complicated and only partially understood multi-step process of cancer progression. A subset cells that can leave the primary tumor, intravasate, circulate to reach distant organs are called circulating tumor (CTCs). Multiple lines evidence suggest in metastatic cells, epithelial mesenchymal markers co-expressed facilitate cells' ability go back forth between cellular states. This feature epithelial-to-mesenchymal plasticity (EMP). CTCs represent unique source understand EMP...